Beam Therapeutics Inc
$ 27.48
0.84%
07 Aug - close price
- Market Cap 2,795,997,000 USD
- Current Price $ 27.48
- High / Low $ 28.35 / 27.13
- Stock P/E N/A
- Book Value 12.48
- EPS -0.69
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.08 %
- 52 Week High 38.26
- 52 Week Low 15.60
About
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$52.23
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-07 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 |
| Reported EPS | -1.18 | -0.91 | 2.33 | -1.1 | -1 | -1.24 | -1.09 | -1.17 | -1.11 | -1.21 | 1.73 | -1.22 |
| Estimated EPS | 1 | -1.01 | -1.01 | -1.01 | -1.09 | -1.17 | -1.2158 | -1.18 | -1.12 | -1.39 | -1.01 | -1.27 |
| Surprise | -2.18 | 0.1 | 3.34 | -0.09 | 0.09 | -0.07 | 0.1258 | 0.01 | 0.01 | 0.18 | 2.74 | 0.05 |
| Surprise Percentage | -218% | 9.901% | 330.6931% | -8.9109% | 8.2569% | -5.9829% | 10.3471% | 0.8475% | 0.8929% | 12.9496% | 271.2871% | 3.937% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BEAM
2026-08-07 15:40:50
Analysts have lowered their revenue expectations for Beam Therapeutics (NASDAQ:BEAM) after the company reported second-quarter results that fell short of estimates. While revenue forecasts for 2026 were significantly cut, loss per share estimates remained steady, and the average price target did not change, suggesting analysts don't foresee a long-term impact on valuation despite the short-term disappointment. The company's revenue is now expected to decline significantly, underperforming the broader biotech industry.
2026-08-06 12:40:59
Beam Therapeutics (BEAM) reported a wider-than-expected loss of $1.18 per share in Q2 2026, missing the Zacks Consensus Estimate of a $1.00 loss, and revenues fell significantly year-over-year. Despite the financial performance, the company is advancing its pipeline, including candidates for sickle cell disease (risto-cel), glycogen storage disease type Ia (BEAM-301), alpha-1 antitrypsin deficiency (BEAM-302), and phenylketonuria (BEAM-304), with several clinical data readouts and regulatory filings anticipated. The company maintains a strong cash position, expected to fund operations into mid-2029.
2026-08-06 12:40:59
Beam Therapeutics reported a wider net loss of US$122.68 million and a revenue shortfall in Q2 2026, yet achieved key clinical milestones including completing dosing for its risto-cel sickle cell trial and dosing the first patient in the BEAM-302 study. The article discusses how these developments, particularly the progress toward a risto-cel BLA filing, shape the company's investment outlook despite ongoing financial losses and potential risks related to conditioning regimens. Beam's investment narrative projects significant revenue and earnings growth by 2029, suggesting a potential 89% upside to its current price according to Simply Wall St's fair value analysis.
2026-08-05 14:18:47
Analysts have cut the average 12-month price target for Beam Therapeutics Inc. (BEAM) stock from $51.36 to $51.07, with individual forecasts ranging from $26 to $80 per share. This updated target suggests an 80% potential upside based on the Aug. 4 closing price. The consensus rating from 16 analysts remains a "Buy," with 14 Buys, 2 Holds, and 0 Sells.
2026-08-05 14:06:38
Beam Therapeutics (BEAM) reported a wider net loss and higher loss per share for Q2 2026, yet saw a short-term share price bounce. Despite a challenging longer-term stock performance, a "Most Popular Narrative" suggests the company is 44.5% undervalued with a fair value of $51.07, driven by expectations for its ESCAPE technology. However, this bullish outlook depends on managing safety concerns and securing funding, and a simpler P/S ratio cross-check raises valuation risks.
2026-08-04 18:16:25
Beam Therapeutics announced the completion of dosing for adult and adolescent patients in its Phase 1/2 BEACON trial for sickle cell disease, with a biologics license application expected by late 2026 and updated data by year-end. The company also reported progress in other trials, including BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-304 for phenylketonuria, and detailed its financial position with $1.2 billion in cash and equivalents.
